systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-339Research ArticleОБЗОРЫКомбинация телмисартана и амлодипина в лечении артериальной гипертонииThe telmisartan and amlodipine combination in the treatment of hypertensionШехянГ. Г.ShehyanG. G.noemail@neicon.ruЯлымовА. А.YalymovA. A.noemail@neicon.ruЩикотаА. М.SchikotaA. M.noemail@neicon.ruЗадионченкоВ. С.ZadionchenkoV. S.noemail@neicon.ruВаренцовС. И.VarentsovS. I.noemail@neicon.ruГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РоссииRussian FederationГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России; ГБУЗ ГКБ №24, филиал №1 Департамента здравоохранения г. МосквыRussian FederationГБУЗ ГКБ №24, филиал №1 Департамента здравоохранения г. МосквыRussian Federation2014231220221116472Copyright © Шехян Г.Г., Ялымов А.А., Щикота А.М., Задионченко В.С., Варенцов С.И., 20222022Шехян Г.Г., Ялымов А.А., Щикота А.М., Задионченко В.С., Варенцов С.И.Shehyan G.G., Yalymov A.A., Schikota A.M., Zadionchenko V.S., Varentsov S.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/339

В представленном обзоре дана оценка социально значимого заболевания - артериальной гипертонии (АГ) - и проблемы поиска эффективной антигипертензивной терапии.Препарат Твинста® (производитель Берингер Ингельхайм Фарма) - современный комбинированный антигипертензивныйпрепарат, который обеспечивает не только эффективный контроль артериального давления, но и за счет доказанного протективного эффекта в отношении всех органов-мишеней улучшает прогноз жизни пациентов с АГ.В клинических исследованиях показано, что комбинация телмисартана и амлодипина обеспечивает дополнительные преимущества при лечении пациентов с метаболическим синдромом (улучшает параметры углеводного и липидного обмена), больных с нарушением функции почек (вызывает регрессию протеинурии), а также с гипертрофией левого желудочка (вызывает регрессию последнего).В недавно завершившихся исследованиях доказано, что телмисартан действует как селективый модулятор PPAR-рецепторов.В представленом обзоре показано, что Твинста® является представителем современных комбинированных антигипертензивныхпрепаратов, имеет доказанный крупными клиническими исследованиями благоприятный профиль эффективности и безопасности.

The following review assesses socially significant disease - hypertension (AH) - and the problem of finding an effective antihypertensive therapy. Twynsta® drug (manufacturer Boehringer Ingelheim Pharma) - modern combined antihypertensive drug, which not only provides effective blood pressure control, but also due to the protective effect has been proved for all target organs improves the life expectancy of patients with hypertension. The clinical studies show that combination of telmisartan and amlodipine provides additional benefits in the treatment of patients with metabolic syndrome (by improving the carbohydrate and lipid metabolism), patients with impaired renal function (by inducing the regression of proteinuria), as well as left ventricular hypertrophy (by causing regression of the latter). The recently completed studies have shown that telmisartan acts as a selective PPAR-receptor modulator.In the present review it is shown that Twynsta® represents modern combined antihypertensive drugs and has a clinically proven favorable efficacy and safety profile.

артериальная гипертониялечениекомбинированные ангигипертензивные препаратытелмисартанамлодипинорганопротективный эффектэффективностьбезопасностьarterial hypertensiontreatmentcombined antihypertensive drugstelmisartanamlodipineorgan effectefficiencysafetyReferencesДиагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3: 5-26.Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3: 5-26.Амосова Е.Н. Блокада рецепторов ангиотензина - новое направление в лечении артериальной гипертензии. Укр. кардіол. журн. 1999; 4: 87-91.Амосова Е.Н. Блокада рецепторов ангиотензина - новое направление в лечении артериальной гипертензии. Укр. кардіол. журн. 1999; 4: 87-91.Задионченко В.С., Шехян Г.Г., Щикота А.М. и др. Особенности комбинированной антигипертензивной терапии в современном лечении артериальной гипертензии. Рус. мед. журн. 2011; 19 (26): 1630-9.Задионченко В.С., Шехян Г.Г., Щикота А.М. и др. Особенности комбинированной антигипертензивной терапии в современном лечении артериальной гипертензии. Рус. мед. журн. 2011; 19 (26): 1630-9.Чазова И.Е. Новые Европейские рекомендации по ведению пациентов с артериальной гипертонией: место сартанов. Системные гипертензии 2008; 2: 4-7.Чазова И.Е. Новые Европейские рекомендации по ведению пациентов с артериальной гипертонией: место сартанов. Системные гипертензии 2008; 2: 4-7.Чазова И.Е., Карпов Ю.А., Остроумова О.Д. Заседание совета экспертов «Новое в комбинированной терапии артериальной гипертензии». Системные гипертензии 2012; 3: 66-8.Чазова И.Е., Карпов Ю.А., Остроумова О.Д. Заседание совета экспертов «Новое в комбинированной терапии артериальной гипертензии». Системные гипертензии 2012; 3: 66-8.Ялымов А.А., Шехян Г.Г., Щикота А.М. и др. Антагонисты кальция в терапии сердечно - сосудистых заболеваний. Участковый терапевт 2012; 5: 7.Ялымов А.А., Шехян Г.Г., Щикота А.М. и др. Антагонисты кальция в терапии сердечно - сосудистых заболеваний. Участковый терапевт 2012; 5: 7.Alizade I.G, Karayeva N.T. The effects of amlodipine on cerebral circulatory values in patients with essential hypertension. Anadolu Kardiyol Derg 2001; 1 (1): 14-6.Alizade I.G, Karayeva N.T. The effects of amlodipine on cerebral circulatory values in patients with essential hypertension. Anadolu Kardiyol Derg 2001; 1 (1): 14-6.ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high - risk hypertensive patients randomized to angiotensin - converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high - risk hypertensive patients randomized to angiotensin - converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.Battershill A.J, Scott L.J. Telmisartan: preparation application in treatment of arterial hypertension. Drugs 2006; 66 (1): 51-83.Battershill A.J, Scott L.J. Telmisartan: preparation application in treatment of arterial hypertension. Drugs 2006; 66 (1): 51-83.Detry J.M. Amlodipine and the total ischemic burden: Circadian Anti-Ischemia Program in Europe (CAPE) trial. Methodology, safety and toleration. Cardiology 1994; 85 (Suppl. 2): 24-30.Detry J.M. Amlodipine and the total ischemic burden: Circadian Anti-Ischemia Program in Europe (CAPE) trial. Methodology, safety and toleration. Cardiology 1994; 85 (Suppl. 2): 24-30.Elmer P.J, Grimm R.Jr, Laing B et al. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prev Med 1995; 24 (4): 378-88.Elmer P.J, Grimm R.Jr, Laing B et al. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prev Med 1995; 24 (4): 378-88.Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan or amlodipine - based regimens: VALUE, a randomised trial. Lancet 2004; 363: 2022-31.Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan or amlodipine - based regimens: VALUE, a randomised trial. Lancet 2004; 363: 2022-31.Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.Mancia G, Parati G, Bilo G et al. Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension 2012; 60: 1400-6.Mancia G, Parati G, Bilo G et al. Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension 2012; 60: 1400-6.Neldam S, Edwards C, Jones R. Switching patients with uncontrolled hypertension on amlodipine 10 mg to single - pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin 2011; 27: 2145-53.Neldam S, Edwards C, Jones R. Switching patients with uncontrolled hypertension on amlodipine 10 mg to single - pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin 2011; 27: 2145-53.Neldam S, Edwards C, Lang M, Jones R for The TEAMSTA-5 and TEAMSTA-10 Investigators.Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40-80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies. Current Ther Res, Clin Exp 2012; 73 (1/2): 65-84.Neldam S, Edwards C, Lang M, Jones R for The TEAMSTA-5 and TEAMSTA-10 Investigators.Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40-80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies. Current Ther Res, Clin Exp 2012; 73 (1/2): 65-84.Neutel J.M, Klein C, Meinicke T.W. Long - term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002;11: 302-9.Neutel J.M, Klein C, Meinicke T.W. Long - term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002;11: 302-9.Neutel J, Mancia G, Black H et al. Single-Pill Combination of Telmisartan/Amlodipine in Patients With Severe Hypertension: Results From the TEAMSTA Severe HTN Study. J Clin Hypertens (Greenwich) 2012; 14 (4): 206-15 (ERRATUM J Clin Hypertens doi: 10.1111/jch.12025).Neutel J, Mancia G, Black H et al. Single-Pill Combination of Telmisartan/Amlodipine in Patients With Severe Hypertension: Results From the TEAMSTA Severe HTN Study. J Clin Hypertens (Greenwich) 2012; 14 (4): 206-15 (ERRATUM J Clin Hypertens doi: 10.1111/jch.12025).Nicholls M.G, Charles C.J, Crozier I.G et al. Blockade of the renin - angiotensin system. J Hypertension 1994; 10 (Suppl.): 95-103.Nicholls M.G, Charles C.J, Crozier I.G et al. Blockade of the renin - angiotensin system. J Hypertension 1994; 10 (Suppl.): 95-103.Nissen S.E., Tuzcu E.M., Libby P et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiorprovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-25.Nissen S.E., Tuzcu E.M., Libby P et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiorprovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-25.Pitt B et al. Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102 (13): 1503-10.Pitt B et al. Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102 (13): 1503-10.Ragot S, Ezzaher A, Meunier A. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVEREST study. J Hum Hypertension 2002; 16: 865-73.Ragot S, Ezzaher A, Meunier A. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVEREST study. J Hum Hypertension 2002; 16: 865-73.Rippin J, Bain S.C, Barnett A.H. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. J Diabetes Complications 2002; 16 (3): 195-200.Rippin J, Bain S.C, Barnett A.H. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. J Diabetes Complications 2002; 16 (3): 195-200.Rossi A, Dikareva A, Bacon S.L, Daskalopoulou S.S. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. J Hypertens 2012; 30: 1277-88.Rossi A, Dikareva A, Bacon S.L, Daskalopoulou S.S. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. J Hypertens 2012; 30: 1277-88.Sharma A.M, Bakris G, Neutel J.M et al. Single - pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized,parallel - group, double - blind trial. Clin Ther 2012; 34: 537-51.Sharma A.M, Bakris G, Neutel J.M et al. Single - pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized,parallel - group, double - blind trial. Clin Ther 2012; 34: 537-51.Smith D.H, Matzek K.M, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacology 2000; 40; 1380-90.Smith D.H, Matzek K.M, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacology 2000; 40; 1380-90.Smith D.H. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin - converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther 2002; 24: 1484-501.Smith D.H. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin - converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther 2002; 24: 1484-501.Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators. Effects of the angiotensin - receptor blocker telmisartan on cardiovascular events in high - risk patients intolerant to angiotensin - converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174-83.Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators. Effects of the angiotensin - receptor blocker telmisartan on cardiovascular events in high - risk patients intolerant to angiotensin - converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174-83.UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J 1998; 317: 703-13.UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J 1998; 317: 703-13.WHO - ISH guidelines for the management of hypertension. J Hypertension 1999; 11;905-16.WHO - ISH guidelines for the management of hypertension. J Hypertension 1999; 11;905-16.

The authors declare that there are no conflicts of interest present.